VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 121 filers reported holding VERVE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $563,550 | -60.3% | 42,500 | -43.8% | 0.00% | -100.0% |
| Q2 2023 | $1,418,813 | +24.9% | 75,670 | -3.9% | 0.00% | – |
| Q1 2023 | $1,135,863 | -25.6% | 78,770 | -0.1% | 0.00% | -100.0% |
| Q4 2022 | $1,526,135 | -39.8% | 78,870 | +6.9% | 0.00% | 0.0% |
| Q3 2022 | $2,534,000 | +312.7% | 73,770 | +83.5% | 0.00% | – |
| Q2 2022 | $614,000 | -21.1% | 40,200 | +17.9% | 0.00% | – |
| Q1 2022 | $778,000 | +52.8% | 34,100 | +147.1% | 0.00% | – |
| Q4 2021 | $509,000 | -32.3% | 13,800 | -13.8% | 0.00% | – |
| Q3 2021 | $752,000 | +100.5% | 16,000 | +157.3% | 0.00% | – |
| Q2 2021 | $375,000 | – | 6,219 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |